Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSIBOOST 2
2023-505700-35-00Phase 2Authorised
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of osimertinib, cobicistat and ritonavir in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoints: Daily cumulative dose reduction while retaining target osimertinib exposure and Central nervous system disease control rate at 12 weeks. Planned start Jul 2024; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505700-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505700-35-00.